Thus far, seven distinct NAB2–STAT6 gene fusion types (NAB2exon2–STAT6exon5, NAB2exon4–STAT6exon2, NAB2exon4–STAT6exon4, NAB2exon5–STAT6exon16, NAB2exon6–STAT6exon16, NAB2exon6–STAT6exon17, and NAB2exon7–STAT6exon2) have been discovered to commonly account for pathologic variation and tumor aggressiveness in SFTs. This evidence concerns the gene NAB2 and neoplasm.